Abstract:e13538 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and more rare or atypical EGFR mutations had been identified. Such as exons 18-25 kinase domain duplications (KDD) and EGFR fusions (EGFR-RAD51 or EGFR-PURB), the importance of EGFR signaling in the pathogenesis of lung cancer and the efficacy of EGFR-TKI treatment had been demonstrated. The aim of this study was to evaluate the prevalence of EGFR fusions in Chinese NSCLC patients, and to study the association between these molecular alterations and clinicopathological characteristics in these patients. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2017. A total of 2410 patients with NSCLC (non-squamous/squamous =2061/349) were screened by using next-generation sequencing (NGS)-based 381 genes panel assay for detecting EGFR fusions. Results: Of this entire cohort, just two (0.08%) patients were identified with an EGFR-SEPT14 fusion and an EGFR-RAD51 fusion. These two patients was that a 62-year-old never smoking female, who was diagnosed with lung adenocarcinoma and a 48-year-old male with a 32 pack-year smoking history, who was diagnosed with lung adenocarcinoma. The first patient: EGFR-SEPT14 fusion driven NSCLC responding to icotinib, there were no treatment-related adverse events, including abnormal hepatic, renal function, gastrointestinal reactions, rashes, and cordis damage. Thus far, after several months, the disease is stable and she is continuing treatment with icotinib; The second patient: EGFR-RAD51 fusion driven NSCLC responding to erlotinib will be presented. The patient was considered to have a partial response (PR) to erlotinib. During treatment with erlotinib, no abnormal hepatic and renal function occurred. Conclusions: The frequency of EGFR fusions in Chinese patients with NSCLC is extremely rare (0.08%). The NGS assay provides a novel diagnostic tool. In the future, we can explore differences in the acquired mechanism underlying EGFR TKIs between sensitive EGFR mutations and other uncommon variant NSCLC patients.

FGFR1 Amplification and EGFR Mutation in Chinese Squamous Cell Lung Cancer.

FGF19 Genetic Amplification As a Potential Therapeutic Target in Lung Squamous Cell Carcinomas.

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

The Role of FGFR1 Gene Amplification As a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.

The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

FGFR Genes Mutation is an Independent Prognostic Factor and Associated with Lymph Node Metastasis in Squamous Non-Small Cell Lung Cancer

Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

Prognostic Value of Fgfr1 Overexpression and Amplification in Esophageal Squamous Cell Carcinoma Patients: A Combined Analysis from Tcga Database

Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis.

Programmed Cell Death-1 (Pd-L1) Expression and Fibroblast Growth Factor Receptor 1 (fgfr1) Amplification in Chinese Stage Iii/Iv Lung Squamous Lung Carcinoma (Sqc).

A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

Epidermal growth factor receptor gene copy number in Chinese patients with non-small cell lung cancer and clinical significance

Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

High Amplification of FGFR1 Gene is a Delayed Poor Prognostic Factor in Early Stage ESCC Patients

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

The Prognostic Value of EGFR Overexpression and Amplification in Esophageal Squamous Cell Carcinoma

Epidermal growth factor receptor gene and protein abnormalities in non-small cell lung cancer